The IV Bags market is projected to grow from USD 4.3 billion in 2025 to USD 5.7 billion in 2030 at a CAGR of 5.7%.
IV bags are pouches containing fluids, electrolytes, vitamins, minerals, and glucose solutions, among others, which are used in administering necessary fluids and nutrients in the body. The demand for IV packs is witnessing positive growth fueled by the growing electrolyte depletion, lack of hydration, and malnutrition problems in individuals, which has bolstered the need for liquid nutrients and alternatives to be injected into the human body.
Furthermore, IV packs are becoming progressively prevalent and favored alternatives for parenteral administration due to their simple accessibility. The cost of an IV sack is roughly $1, which significantly contributes to the market's rising deals.
Moreover, car crashes are one of the leading causes of disability and death worldwide, resulting in up to 50 million injuries and 1.3 million fatalities annually. Across the globe, one in every four deaths is related to walking or bicycling, according to the World Health Organization. Fluid administration is therefore required due to the rising number of surgeries and accidents, which is anticipated to spur market expansion.
Growing chronic disease prevalence is propelling the market demand.
Factors such as the rising prevalence of chronic diseases, the increased number of surgeries and road accidents, and the growing geriatric population are expected to drive market growth during the forecast period. For instance, according to the National Institute of Health in July 2022 stated that around 20% of individuals in western locales, such as North America and Europe, have gastroesophageal reflux illness (GERD) as of 2022. Besides, the predominance of GERD in the US extended from 18.1% to 27.8%
Furthermore, information from the Cancer Realities and Figures 2023 report demonstrates that 297,790 women in the US are expected to get an invasive breast cancer diagnosis in 2023, up from 287,850 cases in 2022. Additionally, the same source states that in 2023, compared to 51,400 cases in 2022, approximately 55,720 women in the US are anticipated to receive a non-invasive (in situ) breast cancer diagnosis. Since cancer treatment deprives the body of nutrition and affects the body by causing ulcers, gastrointestinal dysfunction, and physical blockages, it is anticipated that the demand for IV bags will increase. It increases the need for patients to receive parenteral nutrition, which drives market expansion.
Plastic usage in producing IV bags can act as an obstacle to market growth
IV bags are made of plastic materials such as polyvinyl chloride (PVC), and polypropylene (PP), among other materials. The decomposition rate of such materials is extremely low, thereby making them hazardous for the environment, and with the growing healthcare concern followed by booming medical waste generation, the demand for such materials is expected to slow down shortly, which can limit the scale of IV bags production.
However, with the ongoing shift towards sustainable materials and biocompatibility, various innovations are being made in healthcare equipment, which will steadily propel the market demand and supply for IV bags with high bio-content.
Hospitals, based on end-user, will account for a considerable market share.
By end-users, the hospital is anticipated to constitute a significant market share, fueled by the growing need for effective hospital administration for treating chronic diseases. Increasing cancer surgeries as well as organ transplant procedures also demand infusing intravenous fluids both during and after the completion of transplant surgery, which will lead to the growth of IV bags in the hospital sector in the coming years. As per Health Resources & Services Administration, organdonor.gov, the transplants performed by organs in the U.S. of kidney, liver, pancreas, heart, and lungs were 27,332, 10,660, 102, 812, and 4,545, respectively, as of March 2024. Additionally, increasing launches of new products and approvals from the regulatory bodies also drive the growth of the market.
The demand for IV bags in hospitals will increase with the growing aging population and rise in the prevalence of chronic diseases. Additionally, rising product launches and recycling drives of IV bags collected from hospitals across the country also drive the market for IV bags.
For instance, in December 2023, Baxter International completed the initial phase of its intravenous bag recycling program pilot for U.S. hospitals, partnering with Northwestern Medicine in Chicago. Over six tons of PVC IV bag waste were diverted from landfills for recycling. Similarly, in February 2023, NUH, a large tertiary hospital in Singapore, initiated Singapore's first IV fluid bag recycling drive.
North America will continue to be the dominant market shareholder during the forecast period.
Geographically, the IV bags market has been segmented into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific.
During the forecast period, the North American region is estimated to hold a considerable market share fueled by the growing chronic disease prevalence in the major regional economies, followed by well-established healthcare infrastructure and an increase in the number of surgical procedures and hospital visits. According to the American Hospital Association, in 2022, the strength of hospitals in the United States stood at 6,129, whereas the total number of admissions in U.S. hospitals reached 34,011,386.
Likewise, the increase in the prevalence of surgical procedures has also propelled the market demand; for instance, according to the American Society of Plastic Surgeons[1], in 2023, the total number of surgical procedures reported was 1,575,244, which signified a 5% growth over the figure reported in 2022. Additionally, as per the data provided by the Alberta government, in 2022, the total number of surgeries conducted stood at 292,500, which represented a 13,900 increase over the preceding year’s surgical volume.
January 2026: Baxter International maintained consistent supply assurance for critical IV fluids and bags as part of its core product strategy amid evolving clinical demand conditions.
August 2025: The U.S. FDA declared the country’s IV and injectable saline solution shortage resolved, as Baxter, Fresenius, and B. Braun expanded production and supply networks to restore inventories.
May 2025: ICU Medical, Inc. and Otsuka Pharmaceutical Factory completed the formation of Otsuka ICU Medical LLC, a joint venture to strengthen North American IV solution manufacturing capacity and supply resiliency.
February 2025: B. Braun Medical, Inc. announced an updated allocation and fulfillment process for IV solutions products effective March 1, 2025, aiming to better meet increased hospital demand post-shortage events.
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 4.3 billion |
| Total Market Size in 2030 | USD 5.7 billion |
| Forecast Unit | Billion |
| Growth Rate | 5.7% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Material Type, Capacity, Chamber Type, End-User |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
By Type
PVC
PP
PE
By Capacity
Less than 100 ml
100-250 ml
250-500 ml
500-1000 ml
Above 1000 ml
By Chamber Type
Single Chamber
Multi-Chamber
By End-User
Blood Banks
Hospitals
Ambulatory Services
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Others